Abstract

Alzheimer’s disease (AD) is a severe multifactorial neurodegenerative disorder characterized by a progressive loss of neurons in the brain. Despite research efforts, the pathogenesis and mechanism of AD progression are not yet completely understood. There are only a few symptomatic drugs approved for the treatment of AD. The multifactorial character of AD suggests that it is important to develop molecules able to target the numerous pathological mechanisms associated with the disease. Thus, in the context of the worldwide recognized interest of multifunctional ligand therapy, we report herein the synthesis, characterization, physicochemical and biological evaluation of a set of five (1a–e) new ferulic acid-based hybrid compounds, namely feroyl-benzyloxyamidic derivatives enclosing different substituent groups, as potential anti-Alzheimer’s disease agents. These hybrids can keep both the radical scavenging activity and metal chelation capacity of the naturally occurring ferulic acid scaffold, presenting also good/mild capacity for inhibition of self-Aβ aggregation and fairly good inhibition of Cu-induced Aβ aggregation. The predicted pharmacokinetic properties point towards good absorption, comparable to known oral drugs.

Highlights

  • Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by a progressive loss of neurons in the brain

  • It is wellknown that a common feature in AD patients is the presence of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau protein, the two major hallmarks in AD [3]

  • Iron stock solution was prepared with an excess of acid chloride to avoid hydrolysis and its concentration in HCl was determined by the usual standardaddition method using 0.1M HCl (Titrisol)

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by a progressive loss of neurons in the brain. Symptoms are memory decline and language problems, followed by other cognitive serious dysfunctions related to brain atrophy [1]. AD is the most common cause of dementia and, in 2019, it was estimated that 50 million individuals were affected by dementia worldwide. This number is projected to reach 152 million cases by 2050 [2]. The pathogenesis and mechanism of AD progression are not yet completely understood. It is wellknown that a common feature in AD patients is the presence of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau protein, the two major hallmarks in AD [3]

Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call